MedNet Solutions, a global life sciences technology solutions company specializing in clinical study management systems, and Statistics & Data Corporation (SDC), a specialized Contract Research Organization (CRO) focused exclusively on delivering biostatistics and data management services to the life sciences industry, are pleased to announce that SDC has chosen MedNet’s iMedNet™ EDC platform as their eClinical solution of choice. As the latest member of the iMedNet Partner Program, SDC will be able to couple their personalized service and innovative clinical biometrics expertise with iMedNet EDC’s extensive and highly configurable eClinical toolset to quickly and effectively support their customers’ clinical research initiatives.
“After working together on multiple projects over the past 2 years, SDC is excited to announce the formalization of our partnership with MedNet Solutions,” stated Dr. Richard Abelson, President at SDC. “We believe that the iMedNet platform is a next generation eClinical technology, and our team is looking forward to offering the functionality and flexibility of the system as SDC’s primary solution to our clients.”
“We are extremely pleased to solidify our strategic relationship with SDC – a quality organization committed to exceptional customer service and support,” noted John M. (Rob) Robertson, President and CEO of MedNet Solutions. “iMedNet was selected by SDC after their exhaustive review of the eClinical solutions marketplace…just one example of their keen attention to detail. It is very gratifying that iMedNet was ultimately selected by them as the best EDC system available to meet their requirements.”
For more information on iMedNet EDC or the iMedNet Partner Program, please contact MedNet Solutions. For additional details on SDC’s biostatistics and data management services, please contact SDC
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.